Sage Therapeutic Company Overview
About Sage Therapeutic
Sage Therapeutics (NASDAQ:SAGE) is a biopharmaceutical company focused on the discovery, development, and commercialization of medicines designed to address disorders of the brain. The heart of Sage's mission lies in developing innovative therapies to enhance the lives of patients with central nervous system (CNS) disorders, which range from depression to neurological ailments. Sage's deep commitment to CNS disorders has fueled its drive towards groundbreaking research and the translation of its findings into therapeutic advancements. With a portfolio that includes both approved treatments and drugs under development, Sage Therapeutics strives not only for the advancement of medical science but also for providing hope and improved quality of life for patients grappling with challenging conditions. Through its dedication to innovation and patient care, Sage aims to redefine the treatment landscape for CNS disorders.
Snapshot
Operations
Products and/or services of Sage Therapeutic
- ZULRESSO (brexanolone), the first and only treatment specifically approved for postpartum depression, providing relief within hours.
- SAGE-217 (zuranolone), an investigational oral neurosteroid in development for major depressive disorder and postpartum depression, designed for rapid relief.
- SAGE-324, a next-generation positive allosteric modulator of GABAA receptors, being explored for the potential treatment of essential tremor.
- SAGE-718, the first-in-class oxysterol-based positive allosteric modulator of the NMDA receptor, aimed at addressing cognitive deficits in neurological conditions.
- Collaboration with Biogen to develop and commercialize zuranolone (SAGE-217) and SAGE-324, leveraging Biogen's global neuroscience leadership for accelerating access to groundbreaking therapies.
- Innovative research platform focused on modulating GABA and NMDA receptors, aimed at discovering and developing novel therapies for brain health disorders.
Sage Therapeutic executive team
- Mr. Barry E. GreenePresident, CEO & Director
- Mr. Christopher BenecchiCOO & Treasurer
- Mr. Gregory ShifermanSenior VP, General Counsel & Secretary
- Mr. Michael Quirk Ph.D.Chief Scientific Officer & Interim Head of R&D
- Ms. Ashley KaplowitzDirector of Investor Relations
- Ms. Pamela HerbsterSenior VP and Chief People & Experience Officer
- Dr. Helen ColquhounSenior Vice President of Drug Safety & Pharmacovigilance
- Dr. Aaron Koenig M.D.Medical Director of Early Clinical Development
- Helen RubinsteinInvestor Relations Officer